ArticleFrontiers in aging neuroscience2026
Plasma lncRNA signature of upregulated ATP2B1-AS1 and downregulated RPL21P28 correlates with diagnosis and cognitive severity in Alzheimer's disease.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The non-invasive biomarkers have considerable effects in determination and treatment of Alzheimer's disease (AD). The specificity and stability of the circulating long non-coding RNAs (lncRNAs) have made them suitable options in disease management. The aim of this study was discovering and clinically confirming a new plasma lncRNA signature and the underlying regulatory mechanisms. Methods: In a two-stage research, the preliminary bioinformatic screen of public transcriptomic data (GEO: GSE63060) found candidate lncRNAs. Then the level of the major candidates, ATP2B1-AS1 and RPL21P28, were validated by Real-Time qPCR in plasma of 25 AD patients and 25 healthy controls. The diagnostic performance was appraised by the Receiver Operating Characteristic (ROC) curve analysis and the presumed functions were described by a competing endogenous RNA (ceRNA) network. Results: Our study established concurrent ATP2B1-AS1 upregulation and RPL21P28 downregulation in Alzheimer's patient plasma ( Conclusion: ATP2B1-AS1 and RPL21P28 plasma levels present specific AD biomarker signature. These lncRNAs show great potentials in designing a non-invasive blood test that can be used for early diagnosis and disease follow-up. It also establishes new areas for intervention therapy research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.